Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Facteurs environnementaux dans la maladie de Crohn

Environmental factors in Crohn’s disease


Le facteur d’environnement le mieux caractérisé dans la maladie de Crohn est le tabac, qui non seulement favorise le développement de la maladie, mais aussi en aggrave l’évolution. L’arrêt du tabac a un effet favorable sur l’évolution de la maladie et doit faire partie de la prise en charge thérapeutique au même titre que les traitements médicamenteux d’entretien.

La pilule œstroprogestative et l’appendicectomie n’ont pas d’effet démontré. Le rôle d’autres facteurs environnementaux reste hypothétique bien que les facteurs diététiques, qui sont les plus difficiles à étudier, puissent avoir aussi une importance.


The most important environmental factor recognized in Crohn’s disease is cigarette smoking. Smoking increases the risk of Crohn’s disease and worsens considerably the course of the disease. Conversely, smoking cessation is followed rapidly by reversal of the effect. Persuading patients to stop smoking is probably the most costeffective strategy for controlling disease activity. The contraceptive pill and appendectomy have no effect. The role of other environmental factors remains putative although dietary factors, which are the most difficult to study, may be important.

This is a preview of subscription content, log in to check access.


  1. 1.

    Bjornsson S, Johannsson JH. Inflammatory bowel disease in Iceland, 1990–1994: a prospective, nationwide, epidemiological study. Eur J Gastroenterol Hepatol 2000; 12: 31–8.

  2. 2.

    Calkins BM. A meta-analysis of the role of smoking in inflammatory bowel disease. Dig Dis Sci 1989; 34: 1841–54.

  3. 3.

    Brant SR, Picco MF, Achkar JP, et al. Defining complex contributions of NOD2/CARD15 gene mutations, age at onset, and tobacco use on Crohn’s disease phenotypes. Inflamm Bowel Dis 2003; 9: 281–9.

  4. 4.

    Lindberg E, Jarnerot G, Huitfeldt B. Smoking in Crohn’s disease: effect on localisation and clinical course. Gut 1992; 33: 779–82.

  5. 5.

    Rüssel MG, Volovics A, Schoon EJ, et al. Inflammatory bowel disease: is there any relation between smoking status and disease presentation? European Collaborative IBD Study Group. Inflamm Bowel Dis 1998; 4:182–6.

  6. 6.

    Cosnes J, Carbonnel F, Carrat F, Beaugerie L, Cattan S, Gendre J. Effects of current and former cigarette smoking on the clinical course of Crohn’s disease. Aliment Pharmacol Ther 1999; 13: 1403–11.

  7. 7.

    Rüssel MG, Nieman FH, Bergers JM, Stockbrugger RW. Cigarette smoking and quality of life in patients with inflammatory bowel disease. South Limburg IBD Study Group. Eur J Gastroenterol Hepatol 1996; 8: 1075–81.

  8. 8.

    Cosnes J, Carbonnel F, Beaugerie L, Le Quintrec Y, Gendre JP. Effects of cigarette smoking on the long-term course of Crohn’s disease. Gastroenterology 1996; 110: 424–31.

  9. 9.

    Parsi MA, Achkar JP, Richardson S, et al. Predictors of response to infliximab in patients with Crohn’s disease. Gastroenterology 2002; 123: 707–13.

  10. 10.

    Holdstock G, Savage D, Harman M, Wright R. Should patients with inflammatory bowel disease smoke? Br Med J (Clin Res Ed) 1984; 288: 362.

  11. 11.

    Picco MF, Bayless TM. Tobacco consumption and disease duration are associated with fistulizing and stricturing behaviors in the first 8 years of Crohn’s disease. Am J Gastroenterol 2003; 98: 363–8.

  12. 12.

    Louis E, Michel V, Hugot JP, et al. Early development of stricturing or penetrating pattern in Crohn’s disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype. Gut 2003; 52: 552–7.

  13. 13.

    Breuer-Katschinski BD, Hollander N, Goebell H. Effect of cigarette smoking on the course of Crohn’s disease. Eur J Gastroenterol Hepatol 1996; 8: 225–8.

  14. 14.

    Reif S, Lavy A, Keter D, et al. Lack of association between smoking and Crohn’s disease but the usual association with ulcerative colitis in Jewish patients in Israel: a multicenter study. Am J Gastroenterol 2000; 95: 474–8.

  15. 15.

    Fraga XF, Vergara M, Medina C, Casellas F, Bermejo B, Malagelada JR. Effects of smoking on the presentation and clinical course of inflammatory bowel disease. Eur J Gastroenterol Hepatol 1997; 9: 683–7.

  16. 16.

    Moum B, Ekbom A, Vatn MH, et al. Clinical course during the 1st year after diagnosis in ulcerative colitis and Crohn’s disease. Results of a large, prospective population-based study in southeastern Norway, 1990–93. Scand J Gastroenterol 1997; 32: 1005–12.

  17. 17.

    Cottone M, Rosselli M, Orlando A, et al. Smoking habits and recurrence in Crohn’s disease. Gastroenterology 1994; 106: 643–8.

  18. 18.

    Sutherland LR, Ramcharan S, Bryant H, Fick G. Effect of cigarette smoking on recurrence of Crohn’s disease. Gastroenterology 1990; 98: 1123–8.

  19. 19.

    Moskovitz D, McLeod RS, Greenberg GR, Cohen Z. Operative and environmental risk factors for recurrence of Crohn’s disease. Int J Colorectal Dis 1999; 14: 224–6.

  20. 20.

    Yamamoto T, Keighley MR. The association of cigarette smoking with a high risk of recurrence after ileocolonic resection for ileocecal Crohn’s disease. Surg Today 1999; 29: 579–80.

  21. 21.

    Ryan WR, Allan RN, Yamamoto T, Keighley MR. Crohn’s disease patients who quit smoking have a reduced risk of reoperation for recurrence. Am J Surg 2004; 187: 219–25.

  22. 22.

    Persson PG, Ahlbom A, Hellers G. Inflammatory bowel disease and tobacco smoke—a case-control study. Gut 1990; 31: 1377–81.

  23. 23.

    Zeman MV, Hiraki L, Sellers EM. Gender differences in tobacco smoking: higher relative exposure to smoke than nicotine in women. J Womens Health Gend Based Med 2002; 11: 147–53.

  24. 24.

    Rider V, Abdou NI. Gender differences in autoimmunity: molecular basis for estrogen effects in systemic lupus erythematosus. Int Immunopharmacol 2001; 1: 1009–24.

  25. 25.

    Cosnes J, Nion-Larmurier I, Afchain P, Beaugerie L, Gendre JP. Gender differences in the response of colitis to smoking. Clin Gastroenterol Hepatol 2004; 2: 41–8.

  26. 26.

    Zimmerman DD, Delemarre JB, Gosselink MP, Hop WC, Briel JW, Schouten WR. Smoking affects the outcome of transanal mucosal advancement flap repair of trans-sphincteric fistulas. Br J Surg 2003; 90: 351–4.

  27. 27.

    Cosnes J, Beaugerie L, Carbonnel F, Gendre JP. Smoking cessation and the course of Crohn’s disease: an intervention study. Gastroenterology 2001; 120: 1093–9.

  28. 28.

    Smith MB, Lashner B A, Hanauer SB. Smoking and inflammatory bowel disease in families. Am J Gastroenterol 1988; 83: 407–9.

  29. 29.

    Bridger S, Lee JC, Bjarnason I, Jones JE, Macpherson AJ. In siblings with similar genetic susceptibility for inflammatory bowel disease, smokers tend to develop Crohn’s disease and non-smokers develop ulcerative colitis. Gut 2002; 51: 21–5.

  30. 30.

    Orholm M, Binder V, Sorensen TI, Rasmussen LP, Kyvik KO. Concordance of inflammatory bowel disease among Danish twins. Results of a nationwide study. Scand J Gastroenterol 2000; 35: 1075–81.

  31. 31.

    Pierik M, Yang H, Barmada MM, et al. The IBD international genetics consortium provides further evidence for linkage to IBD4 and shows gene-environment interaction. Inflamm Bowel Dis 2005; 11: 1–7.

  32. 32.

    Finnie IA, Campbell BJ, Taylor BA, et al. Stimulation of colonie mucin synthesis by corticosteroids and nicotine. Clin Sci (Lond) 1996; 91: 359–64.

  33. 33.

    Louvet B, Buisine MP, Desreumaux P, et al. Transdermal nicotine decreases mucosal IL-8 expression but has no effect on mucin gene expression in ulcerative colitis. Inflamm Bowel Dis 1999; 5: 174–81.

  34. 34.

    Green JT, McKirdy HC, Rhodes J, Thomas GA, Evans BK. Intra-luminal nicotine reduces smooth muscle tone and contractile activity in the distal large bowel. Eur J Gastroenterol Hepatol 1999; 11: 1299–304.

  35. 35.

    Suenaert P, Bulteel V, Den Hond E, et al. The effects of smoking and indomethacin on small intestinal permeability. Aliment Pharmacol Ther 2000; 14: 819–22.

  36. 36.

    Thomas GA, Rhodes J, Green J. Nicotine and gastrointestinal disease. Qjm 1996; 89: 485–8.

  37. 37.

    Euler DE, Dave SJ, Guo H. Effect of cigarette smoking on pentane excretion in alveolar breath. Clin Chem 1996; 42: 303–8.

  38. 38.

    Genser D, Kang MH, Vogelsang H, Elmadfa I. Status of lipidsoluble antioxidants and TRAP in patients with Crohn’s disease and healthy controls. Eur J Clin Nutr 1999; 53: 675–9.

  39. 39.

    Otterbein LE, Bach FH, Alam J, et al. Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. Nat Med 2000; 6: 422–8.

  40. 40.

    Godet PG, May GR, Sutherland LR. Meta-analysis of the role of oral contraceptive agents in inflammatory bowel disease. Gut 1995; 37: 668–73.

  41. 41.

    Timmer A, Sutherland LR, Martin F. Oral contraceptive use and smoking are risk factors for relapse in Crohn’s disease. The Canadian Mesalamine for Remission of Crohn’s Disease Study Group. Gastroenterology 1998; 114: 1143–50.

  42. 42.

    Cosnes J, Carbonnel F, Carrat F, Beaugerie L, Gendre JP. Oral contraceptive use and the clinical course of Crohn’s disease: a prospective cohort study. Gut 1999; 45: 218–22.

  43. 43.

    Koutroubakis IE, Vlachonikolis IG, Kapsoritakis A, et al. Appendectomy, tonsillectomy, and risk of inflammatory bowel disease: case-controlled study in Crete. Dis Colon Rectum 1999; 42: 225–30.

  44. 44.

    Frisch M, Biggar RJ. Appendectomy and protection against ulcerative colitis. N Engl J Med 2001; 345: 222–3; discussion 223–224.

  45. 45.

    Duggan AE, Usmani I, Neal KR, Logan RF. Appendicectomy, childhood hygiene, Helicobacter pylori status, and risk of inflammatory bowel disease: a case control study. Gut 1998; 43: 494–8.

  46. 46.

    Feeney MA, Murphy F, Clegg AJ, Trebble TM, Sharer NM, Snook JA. A case-control study of childhood environmental risk factors for the development of inflammatory bowel disease. Eur J Gastroenterol Hepatol 2002; 14: 529–34.

  47. 47.

    Lopez Ramos D, Gabriel R, Cantero Perona J, Moreno Otero R, Fernandez Bermejo M, Mate Jimenez J. Association of MALTectomy (appendectomy and tonsillectomy) and inflammatory bowel disease: a familial case-control study. Rev Esp Enferm Dig 2001; 93: 303–14.

  48. 48.

    Sicilia B, Lopez Miguel C, Arribas F, Lopez Zaborras J, Sierra E, Gomollon F. Environmental risk factors and Crohn’s disease: a population-based, case-control study in Spain. Dig Liver Dis 2001; 33: 762–7.

  49. 49.

    Andersson RE, Olaison G, Tysk C, Ekbom A. Appendectomy is followed by increased risk of Crohn’s disease. Gastroenterology 2003; 124: 40–6.

  50. 50.

    Reif S, Lavy A, Keter D, et al. Appendectomy is more frequent but not a risk factor in Crohn’s disease while being protective in ulcerative colitis: a comparison of surgical procedures in inflammatory bowel disease. Am J Gastroenterol 2001; 96: 829–32.

  51. 51.

    Russel MG, Dorant E, Brummer RJ, et al. Appendectomy and the risk of developing ulcerative colitis or Crohn’s disease: results of a large case-control study. South Limburg Inflammatory Bowel Disease Study Group. Gastroenterology 1997; 113: 377–82.

  52. 52.

    Radford-Smith GL, Edwards JE, Purdie DM, et al. Protective role of appendicectomy on onset and severity of ulcerative colitis and Crohn’s disease. Gut 2002; 51: 808–13.

  53. 53.

    Riegler G, Caserta L, Esposito I, et al. Worse clinical course of disease in Crohn’s patients with previous appendectomy. Eur J Gastroenterol Hepatol 2005; 17: 623–7.

  54. 54.

    Cosnes J, Seksik P, Nion-Larmurier I, Beaugerie L, Gendre JP. Prior appendectomy and the phenotype and course of Crohn’s disease. World J Gastroenterol 2006; 12: 1235–42.

  55. 55.

    Lomer MC, Harvey RS, Evans SM, Thompson RP, Powell JJ. Efficacy and tolerability of a low microparticle diet in a double blind, randomized, pilot study in Crohn’s disease. Eur J Gastroenterol Hepatol 2001; 13: 101–6.

  56. 56.

    Lomer MC, Grainger SL, Ede R, et al. Lack of efficacy of a reduced microparticle diet in a multi-centred trial of patients with active Crohn’s disease. Eur J Gastroenterol Hepatol 2005; 17: 377–84.

  57. 57.

    Gibson PR, Shepherd SJ. Personal view: food for thought— western lifestyle and susceptibility to Crohn’s disease. The FODMAP hypothesis. Aliment Pharmacol Ther 2005; 21: 1399–409.

  58. 58.

    Forbes A, Kalantzis T. Crohn’s disease: the cold chain hypothesis. Int J Colorectal Dis 2005; 1–3.

  59. 59.

    Hugot JP, Alberti C, Berrebi D, Bingen E, Cezard JP. Crohn’s disease: the cold chain hypothesis. Lancet 2003; 362: 2012–5.

  60. 60.

    Baron S, Turck D, Leplat C, et al. Environmental risk factors in paediatric inflammatory bowel diseases: a population based case control study. Gut 2005; 54: 357–63.

  61. 61.

    Van Kruiningen HJ, Joossens M, Vermeire S, et al. Environmental factors in familial Crohn’s disease in Belgium. Inflamm Bowel Dis 2005; 11: 360–5.

  62. 62.

    Lindberg E, Tysk C, Andersson K, Jarnerot G. Smoking and inflammatory bowel disease. A case control study. Gut 1988; 29: 352–7.

  63. 63.

    Yamamoto T, Keighley MR. Smoking and disease recurrence after operation for Crohn’s disease. Br J Surg 2000; 87: 398–404.

  64. 64.

    Katschinski B, Fingerle D, Scherbaum B, Goebell H. Oral contraceptive use and cigarette smoking in Crohn’s disease. Dig Dis Sci 1993; 38: 1596–600.

  65. 65.

    Boyko EJ, Theis MK, Vaughan TL, Nicol-Blades B. Increased risk of inflammatory bowel disease associated with oral contraceptive use. Am J Epidemiol 1994; 140: 268–78.

  66. 66.

    Sandler RS, Wurzelmann JI, Lyles CM. Oral contraceptive use and the risk of inflammatory bowel disease. Epidemiology 1992; 3: 374–8.

  67. 67.

    Persson PG, Leijonmarck CE, Bernell O, Hellers G, Ahlbom A. Risk indicators for inflammatory bowel disease. Int J Epidemiol 1993; 22: 268–72.

  68. 68.

    Lashner BA, Kane SV, Hanauer SB. Lack of association between oral contraceptive use and Crohn’s disease: a communitybased matched case-control study. Gastroenterology 1989; 97: 1442–7.

  69. 69.

    Russel MG, Engels LG, Muris JW, et al. Modern life’ in the epidemiology of inflammatory bowel disease: a case-control study with special emphasis on nutritional factors. Eur J Gastroenterol Hepatol 1998; 10: 243–9.

  70. 70.

    Wright JP. Factors influencing first relapse in patients with Crohn’s disease. J Clin Gastroenterol 1992; 15: 12–6.

  71. 71.

    Sutherland LR, Ramcharan S, Bryant H, Fick G. Effect of oral contraceptive use on reoperation following surgery for Crohn’s disease. Dig Dis Sci 1992; 37: 1377–82.

  72. 72.

    Mate-Jimenez J, Correa-Estan JA, Perez-Miranda M, Gomez-Cedenilla A, Pajares JM, Moreno-Otero R. Tonsillectomy and inflammatory bowel disease location. Eur J Gastroenterol Hepatol 1996; 8: 1185–8.

  73. 73.

    Wurzelmann JI, Lyles CM, Sandler RS. Childhood infections and the risk of inflammatory bowel disease. Dig Dis Sci 1994; 39: 555–60.

  74. 74.

    Smithson JE, Radford-Smith G, Jewell GP. Appendectomy and tonsillectomy in patients with inflammatory bowel disease. J Clin Gastroenterol 1995; 21: 283–6.

  75. 75.

    D’Inca R, Varnier M, Mestriner C, Martines D, D’Odorico A, Sturniolo GC. Effect of moderate exercise on Crohn’s disease patients in remission. Ital J Gastroenterol Hepatol 1999; 31: 205–10.

  76. 76.

    Robinson RJ, Krzywicki T, Almond L, et al. Effect of a lowimpact exercise program on bone mineral density in Crohn’s disease: a randomized controlled trial. Gastroenterology 1998; 115: 36–41.

  77. 77.

    Loudon CP, Corroll V, Butcher J, Rawsthorne P, Bernstein CN. The effects of physical exercise on patients with Crohn’s disease. Am J Gastroenterol 1999; 94: 697–703.

  78. 78.

    Corrao G, Tragnone A, Caprilli R, et al. Risk of inflammatory bowel disease attributable to smoking, oral contraception and breastfeeding in Italy: a nationwide case-control study. Cooperative Investigators of the Italian Group for the Study of the Colon and the Rectum (GISC). Int J Epidemiol 1998; 27: 397–404.

  79. 79.

    Bergstrand O, Hellers G. Breast-feeding during infancy in patients who later develop Crohn’s disease. Scand J Gastroenterol 1983; 18: 903–6.

  80. 80.

    Thompson NP, Pounder RE, Wakefield AJ. Perinatal and childhood risk factors for inflammatory bowel disease: a casecontrol study. Eur J Gastroenterol Hepatol 1995; 7: 385–90.

  81. 81.

    Gilat T, Hacohen D, Lilos P, Langman MJ. Childhood factors in ulcerative colitis and Crohn’s disease. An international cooperative study. Scand J Gastroenterol 1987; 22: 1009–24.

  82. 82.

    Klement E, Cohen RV, Boxman J, Joseph A, Reif S. Breastfeeding and risk of inflammatory bowel disease: a systematic review with meta-analysis. Am J Clin Nutr 2004; 80: 1342–52.

  83. 83.

    Ekbom A, Wakefield AJ, Zack M, Adami HO. Perinatal measles infection and subsequent Crohn’s disease. Lancet 1994; 344: 508–10.

  84. 84.

    Ekbom A, Daszak P, Kraaz W, Wakefield AJ. Crohn’s disease after in-utero measles virus exposure. Lancet 1996; 348: 515–7.

  85. 85.

    Pardi DS, Tremaine WJ, Sandborn WJ, et al. Early measles virus infection is associated with the development of inflammatory bowel disease. Am J Gastroenterol 2000; 95: 1480–5.

  86. 86.

    Pardi DS, Tremaine WJ, Sandborn WJ, Loftus EV, Jr., Poland GA, Melton LJ, 3rd. Perinatal exposure to measles virus is not associated with the development of inflammatory bowel disease. Inflamm Bowel Dis 1999; 5: 104–6.

  87. 87.

    Haslam N, Mayberry JF, Hawthorne AB, Newcombe RG, Holmes GK, Probert CS. Measles, month of birth, and Crohn’s disease. Gut 2000; 47: 801–3.

  88. 88.

    Jones P, Fine P, Piracha S. Crohn’s disease and measles. Lancet 1997; 349: 473.

Download references

Author information

Correspondence to J. Cosnes.

About this article

Cite this article

Cosnes, J., Seksik, P. Facteurs environnementaux dans la maladie de Crohn. Acta Endosc 36, 679–688 (2006). https://doi.org/10.1007/BF03018510

Download citation


  • appendicectomie
  • maladie de Crohn
  • tabac


  • appendectomy
  • Crohn’s disease
  • smoking